CB2 Insights Inc. (CSE:CBII,Forum) released its Q3 2019 results on Friday. The medical cannabis Company reported record revenue of $4.2 million (CAD) and sequential growth of 29%.
For more on these results, click here.
CB2's Electronic Data capture softwarewas recently selected to manage the medical cannabis patient data of MyAccess Clinics (a subsidiary of Althea Group Holdings Ltd (ASX:AGH)) in the UK
FULL DISCLOSURE: CB2 Insights Inc. is a client of Stockhouse Publishing.